Three Firms Guide Catalent's $140M Pharma Biz Buy
By Darcy Reddan ( July 3, 2018, 6:22 PM EDT) -- Drug development and delivery company Catalent Inc. said on Tuesday that it has agreed to acquire Juniper Pharmaceuticals Inc. in a deal that carries an equity value of approximately $139.6 million on a fully diluted basis and was guided by Goodwin Procter LLP....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.